|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There are no significant differences between the patients with PC and BP regarding mean age or mean ionized calcium levels but differences were seen in sex distribution and mean parathyroid hormone (PTH) levels.
|
31767140 |
2020 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Even though parathyroid carcinoma is very uncommon in children with good prognosis, this diagnosis has to be considered when a child has severe hypercalcemia, elevated parathyroid hormone and palpable neck mass.
|
31185342 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Primary hyperparathyroidism can be rarely caused by a parathyroid carcinoma; these patients are generally characterized by severe symptoms, large neck lesions and high levels of PTH and calcium.
|
30198445 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When the PTH level is elevated or is not depressed despite the hypercalcemia, findings that suggest family history of hypercalcemia due to a genetic cause include syndromic manifestations in the patient or family members, parathyroid cancer (either suspected before surgery or confirmed during parathyroidectomy), multiple or recurrent parathyroid tumors, a family history of primary hyperparathyroidism, and the onset of primary hyperthyroidism before 50 years of age.
|
30300686 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several mechanisms have been implicated in the development of hypercalcemia of malignancy amongst them the osteolytic related hypercalcemia, parathyroid hormone-related peptide (PTHrP) mediated hypercalcemia, extrarenal 1,25 dixydroxyvitamin D (calcitriol) mediated hypercalcemia and parathyroid hormone (PTH) related hypercalcemia either ectopic in origin or in patients with parathyroid carcinoma.
|
31826272 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical manifestations of PC are primarily due to the excessive secretion of PTH by the tumor rather than spread to local or distant organs.
|
30641523 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum PTH and CgA serve as circulating biomarkers in parathyroid carcinoma, and raised levels of PTH and CgA together with locoregional lymphadenopathy may indicate parathyroid carcinoma.Further studies are needed.
|
30290620 |
2018 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The diagnosis of PC is commonly made after surgery, however there are some clinical/biochemical features that should raise the suspicion of PC, namely markedly elevated serum calcium and PTH levels, a large parathyroid lesion with suspected ultrasonographic features of malignancy, the damages of kidney and bones.
|
30551989 |
2018 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For early detection of recurrence; long-term clinical follow-up with interval measurements of serum calcium and PTH is recommended.Localising studies of PC are helpful.
|
30567092 |
2018 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism (PHPT) is defined by inappropriate elevation of parathormone, caused by parathyroid hyperplasia, also known as multi-gland disease (MGD), parathyroid adenoma (PA), or parathyroid carcinoma (PC).
|
28362510 |
2018 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GCM2-associated primary hyperparathyroidism patients have greater preoperative parathyroid hormone levels, a greater rate of multigland disease, a lesser rate of biochemical cure, and a substantial risk of parathyroid carcinoma.
|
29108698 |
2018 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This investigation of 17 consecutive patients with parathyroid cancer, (re-)operated on at a tertiary referral center between 1994 and July 2016, with a mean follow-up of 179.6 months (15 years) aimed to clarify the suitability of PTH serum levels for prediction of clinical outcome after comprehensive operative management of parathyroid cancer.
|
28525934 |
2017 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
About 90% of PCas are hormonally active hypersecreting parathormone (PTH); consequently patients present with complications of severe hypercalcemia.
|
28157158 |
2017 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum parathyroid hormone and calcium levels are high in the majority of parathyroid carcinoma patients.
|
27744598 |
2017 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cinacalcet can also suppress PTH secretion due to parathyroid carcinoma in the same way as it does for parathyroid hyperplasia in the uremic condition.
|
29047366 |
2017 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preoperatively, calcium and parathyroid hormone concentrations were higher in PC compared to APA and PA (1.76, 1.56 and 1.44 mmol/l, p < .001; and 989, 355 and 160 μmol/l, p < .001, respectively).Calcium was ≤1.77 mmol/l for all PAs.
|
28362521 |
2017 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with PC usually present markedly elevated serum calcium and PTH.
|
27001435 |
2016 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Investigations showed elevated serum parathyroid hormone and calcium levels, and a technetium 99m sestamibi parathyroid scan showed increased activity at the site of the lower left gland that proved to be a substernal parathyroid carcinoma.
|
25511968 |
2015 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histopathological examination revealed parathyroid carcinoma.PTH level dropped to 5.74 pg/mL.
|
22538754 |
2012 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MIR517C showed the most significant difference in expression between Ca and Ad (P=0.0003) and it positively correlated with serum calcium, parathormone and tumour weight.
|
22767050 |
2012 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation.
|
21521290 |
2011 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, using case records from four cases of unequivocal parathyroid carcinoma, we compared intraoperative PTH kinetics of these patients to 475 patients with benign PHPT, and show that intraoperative PTH monitoring is accurate in predicting postoperative normocalcemia in initial en bloc operations for parathyroid carcinoma.
|
20051478 |
2010 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Severe hypercalcemia and its related clinical symptoms, extremely high levels of parathyroid hormone, osteitis fibrosa cystica, a palpable neck mass, and a relatively large depth-width ratio on ultrasonography, are the important features of parathyroid carcinoma.
|
19350316 |
2009 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The case illustrates the difficulties that may be encountered in localising the source of PTH secretion; the patient underwent four unsuccessful exploratory operations of the neck and mediastinum before further investigations revealed a single metastatic deposit of parathyroid carcinoma involving the first thoracic vertebra.
|
9497883 |
1997 |
|
Parathyroid Gland Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of PTH mRNA in oxyphil change and parathyroid carcinoma was also investigated.
|
1744796 |
1991 |